Accordingly, the monitoring of PD-L1 after gemcitabine treatment in CCA would be necessary, possibly by using the non-invasive quantifications, i.e., liquid biopsy or positron emission tomography (PET). Here, CD274 is linked to cholangiocarcinoma.